{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:26:49Z","timestamp":1791487609982,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaci.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T10:56:38Z","timestamp":1649933798000},"page":"1855-1865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022"],"prefix":"10.1016","volume":"149","author":[{"given":"Michel","family":"Arock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.04.004_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib2","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2022.04.004_bib3","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":"Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0022-1759(95)00034-8","article-title":"Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and CD117\/c-kit","volume":"182","author":"Willheim","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2022.04.004_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-1568-2_7","article-title":"Mast cells in human health and disease","volume":"1220","author":"DeBruin","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jaci.2022.04.004_bib6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2022.04.004_bib7","first-page":"965","article-title":"The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others","volume":"142","author":"Galli","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2022.04.004_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0625.1995.tb00254.x","article-title":"Cytokines involved in growth and differentiation of human basophils and mast cells","volume":"4","author":"Valent","year":"1995","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2022.04.004_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/gut.38.1.104","article-title":"Effect of c-kit ligand, stem cell factor, on mediator release by human intestinal mast cells isolated from patients with inflammatory bowel disease and controls","volume":"38","author":"Bischoff","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2022.04.004_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/10428190290012065","article-title":"Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria","volume":"43","author":"Jordan","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2022.04.004_bib11","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jaci.2022.04.004_bib12","first-page":"159","article-title":"Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology","volume":"3","author":"Valent","year":"2013","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jaci.2022.04.004_bib13","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib14","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib15","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1373\/clinchem.2006.068205","article-title":"Sensitive detection of KIT D816V in patients with mastocytosis","volume":"52","author":"Tan","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.jaci.2022.04.004_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2022.04.004_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.04.004_bib19","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13865","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"175","author":"Pardanani","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/ijms22010411","article-title":"Clinical impact of inherited and acquired genetic variants in mastocytosis","volume":"22","author":"Nedoszytko","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2022.04.004_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/thno.51872","article-title":"Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis","volume":"11","author":"Kluin-Nelemans","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2022.04.004_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis\u2014in\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.004_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/pde.12381","article-title":"Novel R634W c-kit mutation identified in familial mastocytosis","volume":"32","author":"Pollard","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2022.04.004_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13578-016-0120-8","article-title":"Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis","volume":"6","author":"Ke","year":"2016","journal-title":"Cell Biosci"},{"key":"10.1016\/j.jaci.2022.04.004_bib27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.06.060","article-title":"Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis","volume":"129","author":"Hartmann","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2022.04.004_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bjh.17405","article-title":"Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series","volume":"193","author":"Tanasi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ajhg.2020.12.007","article-title":"Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis","volume":"108","author":"Galat\u00e0","year":"2021","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2022.04.004_bib30","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/ijms22052586","article-title":"Molecular background, clinical features and management of pediatric mastocytosis: status 2021","volume":"22","author":"Lange","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2022.04.004_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/ped.2013.0275","article-title":"Pediatric mastocytosis: a review of the literature","volume":"26","author":"Frieri","year":"2013","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jaci.2022.04.004_bib32","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.jaip.2020.12.019","article-title":"Criteria for the regression of pediatric mastocytosis: a long-term follow-up","volume":"9","author":"Polivka","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.004_bib33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ijd.15542","article-title":"Natural evolution in pediatric cutaneous mastocytosis: 10-year follow-up","volume":"60","author":"Czarny","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2022.04.004_bib34","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jid.2020.12.030","article-title":"Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis","volume":"141","author":"Aberer","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2022.04.004_bib35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jaip.2020.12.022","article-title":"Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin","volume":"9","author":"Fuchs","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.004_bib36","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib37","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib38","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.004_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Alvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.004_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.anai.2021.06.019","article-title":"Inherited and acquired determinants of serum tryptase levels in humans","volume":"127","author":"Lyons","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.04.004_bib41","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.jaip.2021.03.005","article-title":"The genetic basis and clinical impact of hereditary alpha-tryptasemia","volume":"9","author":"Luskin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.004_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.004_bib43","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.004_bib44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.004_bib46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib49","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib50","doi-asserted-by":"crossref","first-page":"66299","DOI":"10.18632\/oncotarget.11812","article-title":"Mast cell sarcoma: new cases and literature review","volume":"7","author":"Monnier","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2022.04.004_bib51","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2022.04.004_bib52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2022.04.004_bib53","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2009-06-226027","article-title":"Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations","volume":"116","author":"Yang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib54","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.04.004_bib56","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J Pathol"},{"key":"10.1016\/j.jaci.2022.04.004_bib57","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib58","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-018-0346-z","article-title":"KIT D816 mutated\/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis","volume":"33","author":"Jawhar","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib59","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2015-07-655100","article-title":"KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression","volume":"127","author":"Garcia-Montero","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/ehm.12.12","article-title":"Diagnosis, progression patterns and prognostication in mastocytosis","volume":"5","author":"Sperr","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib61","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2021012694","article-title":"Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis","volume":"139","author":"Henriques","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib62","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","article-title":"Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F","volume":"10","author":"Sotlar","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jaci.2022.04.004_bib64","first-page":"197","article-title":"Systemic mastocytosis associated with essential thrombocythemia","volume":"53","author":"Dobrea","year":"2012","journal-title":"Rom J Morphol Embryol"},{"key":"10.1016\/j.jaci.2022.04.004_bib65","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajh.24075","article-title":"KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance","volume":"90","author":"Schwaab","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib66","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12288-019-01225-3","article-title":"Systemic mastocytosis with associated primary myelofibrosis","volume":"36","author":"Greco","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.jaci.2022.04.004_bib67","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjh.17567","article-title":"Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations","volume":"194","author":"Naumann","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib68","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.04.004_bib69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Hanssens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.04.004_bib70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: an emerging challenge in applied hematology","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaci.2022.04.004_bib71","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ajh.24426","article-title":"Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib72","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.04.004_bib73","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib74","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.3390\/ijms22062964","article-title":"Epigenetic changes in neoplastic mast cells and potential impact in mastocytosis","volume":"22","author":"Reszka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2022.04.004_bib75","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Munoz-Gonzalez","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2022.04.004_bib76","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/leu.2017.183","article-title":"SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis","volume":"32","author":"Martinelli","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib78","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: mutation-adjusted risk score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2022.04.004_bib79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jaci.2022.04.004_bib80","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.25265","article-title":"Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases","volume":"93","author":"Shah","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.04.004_bib81","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2022.04.004_bib82","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2022.04.004_bib83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-019-0189-5","article-title":"World Health Organization class-independent risk categorization in mastocytosis","volume":"9","author":"Pardanani","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaci.2022.04.004_bib84","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.jaip.2020.05.005","article-title":"Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis","volume":"8","author":"Schwaab","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.04.004_bib85","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the\u00a0European\u00a0Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2022.04.004_bib86","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/eci.12607","article-title":"Impact of centralized evaluation of bone marrow histology in systemic mastocytosis","volume":"46","author":"Jawhar","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaci.2022.04.004_bib87","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/ijms20122976","article-title":"Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2022.04.004_bib88","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/10428194.2019.1703974","article-title":"New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019","volume":"61","author":"Arock","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2022.04.004_bib89","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.04.004_bib90","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.jaci.2022.04.004_bib91","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3324\/haematol.2019.217950","article-title":"Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis","volume":"105","author":"Greiner","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.04.004_bib92","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.04.004_bib93","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922004869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922004869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:35:18Z","timestamp":1758792918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922004869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0091674922004869"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.04.004","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}